Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Bob who wrote (217)	5/4/1998 11:18:00 PM
From: Steve	Respond to of 496

I have read the Company's annual report and proxy materials and have the following observations: 1) Why increase authorized shares when there are more sellers than buyers of the stock that's already issued and outstanding. When they issued stock in 1997 the stock had demand in the $25 to $30 range so that it enabled the Company to issue new stock at $20. If they issue more stock in the next 12 months with the stock trading down here I wonder what they will fetch for a newly minted share. Maybe they are thinking another stock split. 2) I truly believe that the zero-cost collar entered into by Dr. Smith is a bad sign to wall street. He must be making a killing on the puts he purchased from the covered call proceeds. I wish I was as smart as him to buy puts last year. 3) Wouldn't this Company and its stated goal--to be the world's most creative and productive biopharmaceutical company--fit nicely as a subsidiary of a large pharmaceutical company. From what I hear, research and scientific talent is becoming more difficult to find these days. There are two few resources for way too many biotechs. Where are the consolidators? The recent WSJ article discussing Neuroimmunophilin Ligands seemed to give those who were smart enough a short opportunity. I have to believe that the article was part of a IR campaign that did nothing for the stock. What next? Does the announcement today of the EMND inhibitors for choking-off cancerous tumors spell an end to GLFD's polymer delivery program?

To: Dr. Bob who wrote (217)	5/13/1998 1:50:00 PM
From: bill small	Read Replies (1) \| Respond to of 496

hi Dr Bob, there was an article in the Balto Sun today summarizing the GLFD presentation at the Alex Brown conference yesterday. Company said they expect to start trial of a gel with taxol for ovarian cancer. To start late this year or next. Also stated market penetration of Gliadel wafer for brain cancer after surgery improved during the 1Q 98. 30 % of potential patients for it are receiving it. Impressive I think and holds promise for success of broader applications in the future. best of luck.....Bill